BMS and Pfizer announce global real-world data program and present new analyses of Eliquis at the American College of Cardiology’s 65th Annual Scientific Session

Seventeen abstracts to be presented, including new analyses from the Phase III ARISTOTLE and AMPLIFY clinical studies and from real-world databases.

“The Alliance is pleased to present new analyses from both Phase III clinical trials and real-world databases at this important cardiology conference,” said Douglas Manion, head of specialty development, BMS. “Clinical trial data help to evaluate the safety and efficacy of Eliquis under well-controlled circumstances, while real-world data can offer additional insight into the use of Eliquis for its approved indications in routine clinical practice.”

The real-world data to be presented at ACC.16 are part of ACROPOLIS (Apixaban ExperienCe Through Real-WOrld POpuLatIon Studies), a global real-world data research program designed to further evaluate the effectiveness and safety of Eliquis in routine clinical practice. “Retrospective analyses of real-world data add an important component to our knowledge of Eliquis and may help to inform healthcare practitioners in their treatment decisions,” said Rory O’Connor, senior vice president and head of Global Medical Affairs, Global Innovative Pharmaceuticals Business, Pfizer Inc.